MS & Immune Disorders

Filter Your Results

 

News

 

FDA Approves Amifampridine for Lambert-Eaton Myasthenic Syndrome

Monday, December 03, 2018—The FDA has approved amifampridine (Firdapse, Catalyst Pharmaceuticals, Coral Gables, FL) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. This…

Warning Issued for Possible Stroke Risk When Starting Alemtuzumab

Friday, November 30, 2018—The Food and Drug Administration (FDA) has issued a warning about possible risk of stroke and neurovascular injury for patients starting treatment with alemtuzumab (Lemtrada, …

Biases in Dementia Screening Tools

Wednesday, November 28, 2018—Brief cognitive tests are useful screening tools for dementia in the primary care setting; however, a study published in the journal Neurology Clinical Practice show…

Possible Therapy for Polio-Like Illness Is Not Effective

Tuesday, November 13, 2018—In new research on a potential treatment for acute flaccid myelitis, the antidepressant fluoxetine showed no efficacy. The study, published in the November 9, 2018 online issu…

New Data Available on Risk of Relapse During Pregnancy for Women With Multiple Sclerosis

Tuesday, October 23, 2018—Multiple sclerosis (MS) most often affects women of childbearing age, making family planning and management of the disease before, during, and after pregnancy a primary concer…

Evobrutinib—A First-in-Class Drug—Shows Efficacy in Phase 2 Clinical Trials

Friday, October 12, 2018—October 12, 2018 -- At the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, German October 10-12, results from a double-blind pl…

Dimethyl Fumarate Has Low Risk of Progressive Multifocal Leukoencephalopathy, Short Duration of Lymphopenia, and Long-Term Efficacy for Relapsing Multiple Sclerosis

Friday, October 12, 2018—At the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, Germany October 10-12, results were reported from an integrated analysi…

Cladribine Extension Trial and Post Hoc Analysis Shows 10-Year Safety and Efficacy

Friday, October 12, 2018—In data presented at the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, Germany Oct. 10-12, real-world follow up and post-hoc …

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC